Arbutus Biopharma Corporation - $ABUS STOCK NEWS

Arbutus Biopharma reported its first quarter 2024 financial results and corporate update, highlighting progress in advancing its HBV assets, particularly imdusiran and AB-101. The company has a strong financial position with expected cash runway extended through the second quarter of 2026. End-of-treatment data from Phase 2a combination clinical trials with imdusiran will be presented at the EASL Congress in June 2024. Court ruling in the ongoing patent infringement lawsuit against Moderna was in favor of Arbutus. The company's revenue declined in Q1 2024 compared to the same period in 2023, primarily due to lower license revenue and royalties. Despite an increase in operating expenses, including research and development costs, the net loss for Q1 2024 was $17.9 million.

Arbutus Biopharma announced the retirement of Dr. Michael Sofia, its Chief Scientific Officer, effective December 31, 2024. Dr. Sofia, a renowned antiviral drug discovery scientist, co-founded the company and played a important role in developing potential cures for chronic HBV. The company expressed gratitude for his contributions and emphasized its commitment to continue clinical development under new leadership.

Arbutus Biopharma (Nasdaq: ABUS) will report its first quarter 2024 financial results and provide a corporate update on May 2, 2024. The company aims to develop a functional cure for chronic hepatitis B virus infection.

Arbutus Biopharma (ABUS) issues a statement on the claim construction ruling by the U.S. District Court regarding the lawsuit against Moderna, Inc. The Court's Opinion addresses key patent claims related to Moderna's COVID-19 vaccine, MRNA-1273.

Arbutus Biopharma Corporation (ABUS) announced participation in investor conferences to discuss its progress in developing a functional cure for chronic hepatitis B virus infection.

Arbutus Biopharma Corporation (Nasdaq: ABUS) reports strong financial position with cash and investments of $132M, plans for key clinical data in 2024, and ongoing Phase 2a trials with imdusiran and AB-101.

Arbutus Biopharma Corporation (ABUS) announced the schedule for its Q4 and year-end 2023 financial results and corporate update, set for February 29, 2024. The company aims to develop a functional cure for chronic hepatitis B virus infection leveraging its virology expertise.

Arbutus Biopharma Corporation (ABUS) announced its 2024 business outlook, including clinical development milestones for its HBV pipeline and a financial update. The company's strong balance sheet and anticipated clinical trial readouts position it well towards achieving its mission of developing a functional cure for patients with chronic hepatitis B virus (cHBV). The Phase 2a program for imdusiran, the company's RNAi therapeutic, reinforces the potential role of imdusiran as a cornerstone in a treatment regimen to functionally cure patients with cHBV. Additionally, AB-101, the company's oral PD-L1 inhibitor, continues to progress, with preliminary data expected from the ongoing Phase 1a/1b clinical trial. Arbutus also provided an update on the claim construction hearing for Moderna LNP litigation and its strong financial position with a cash runway into Q1 2026.

Arbutus Biopharma Corporation (ABUS) and Barinthus Biotherapeutics plc (BRNS) announced a late breaking poster presentation at The American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting® 2023, presenting preliminary data from the Phase 2a clinical trial (AB-729-202) combining Arbutus’ RNAi therapeutic, imdusiran, with Barinthus Bio's T-cell stimulating immunotherapeutic, VTP-300, and standard-of-care nucleos(t)ide analogue (NA) therapy. The data showed a meaningful reduction of HBsAg levels, robust reductions of HBsAg during the imdusiran treatment period, and preliminary immunology data suggesting HBV-specific T cell IFN-γ production is enhanced in patients receiving imdusiran plus VTP-300 compared to placebo.